This test evaluates how your body responds to GLP-1 receptor signaling and other peptide pathways, informing whether semaglutide alone, combination therapy with metformin, or alternative compounds like tirzepatide may serve you best
Reuben A, Tillman H, Fontana RJ, Davern T, McGuire B, Stravitz RT, Durkalski V, Larson AM, Liou I, Fix O, Schilsky M, McCashland T, Hay JE, Murray N, Shaikh OS, Ganger D, Zaman A, Han SB, Chung RT, Smith A, Brown R, Crippin J, Harrison ME, Koch D, Munoz S, Reddy KR, Rossaro L, Satyanarayana R, Hassanein T, Hanje AJ, Olson J, Subramanian R, Karvellas C, Hameed B, Sherker AH, Robuck P, Lee WM
Taking another glucagon-like peptide-1 agonist can increase the risk of an overdose and dangerously low blood sugar, or hypoglycemia
Glutaminolysis as a target for cancer therapy
David: Back to this whole Nobel Prize thing, which as we said, was awarded to Banting and Assistant Medical School Dean John Mcleod
It functions as both a GIP and GLP-1 receptor agonist